Alan D. Irvine

Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease

Orismilast, a phosphodiesterase 4B/D inhibitor, in moderate-to-severe atopic dermatitis: efficacy and safety from a multicentre randomized placebo-controlled phase IIb dose-ranging study (ADESOS)

Ultrastrong <i>Staphylococcus aureus</i> adhesion to human skin: Calcium as a key regulator of noncovalent interactions

Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions

Gene–Environment Interaction Affects Risk of Atopic Eczema: Population and In Vitro Studies

Caution regarding interpretation of trends for the global burden of atopic dermatitis and asthma: a critically appraised topic

Impact of climate change on atopic dermatitis: A review by the International Eczema Council

A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema Council

Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration

The Alopecia Areata Severity and Morbidity Index (ASAMI) Study

An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024

Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials

Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis

More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis

Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study

Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial

A concept for integrated care pathways for atopic dermatitis—A GA²LEN ADCARE initiative

Genotypes and phenotypes heterogeneity in PIK3CA-related overgrowth spectrum and overlapping conditions: 150 novel patients and systematic review of 1007 patients with PIK3CA pathogenetic variants

Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trial

Disease characteristics, comorbidities, treatment patterns and quality of life impact in children &lt;12 years old with atopic dermatitis: Interim results from the PEDISTAD Real-World Registry

The effects of systemic immunomodulatory treatments on <scp>COVID</scp>‐19 outcomes in patients with atopic dermatitis: Results from the global <scp>SECURE‐AD</scp> registry

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

The Role of the Environment and Exposome in Atopic Dermatitis

Four childhood atopic dermatitis subtypes identified from trajectory and severity of disease and internally validated in a large UK birth cohort

A Global eDelphi Exercise to Identify Core Domains and Domain Items for the Development of a Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS)

Dermatology COVID-19 Registries

Atopic dermatitis

The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata

Systemic treatments in the management of atopic dermatitis: A systematic review and meta‐analysis

The Alopecia Areata Consensus of Experts (ACE) study part II: Results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata